Development Status and Prospects of the Guidance System for Rare Disease Drugs in China

Sha Mingquan, Sun Tanlin, Lu Jian, Xia Wenjing, Liu Dan, Bai Yu

Chinese Pharmaceutical Affairs ›› 2026, Vol. 40 ›› Issue (8) : 890-897.

PDF(1022 KB)
PDF(1022 KB)
Chinese Pharmaceutical Affairs ›› 2026, Vol. 40 ›› Issue (8) : 890-897. DOI: 10.16153/j.1002-7777.2025-11-0054
Assessment Techniques & Guidance

Development Status and Prospects of the Guidance System for Rare Disease Drugs in China

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2026, 40(8): 890-897 https://doi.org/10.16153/j.1002-7777.2025-11-0054

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(1022 KB)

Accesses

Citation

Detail
Sections
Recommended
京ICP备17052540号-7
Copyright © Chinese Pharmaceutical Affairs, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉